Alnylam Pharmaceuticals Inc. (ALNY)

121.42
NASDAQ : Health Technology
Prev Close 119.86
Day Low/High 118.89 / 121.47
52 Wk Low/High 45.00 / 147.63
Avg Volume 944.10K
Exchange NASDAQ
Shares Outstanding 98.33M
Market Cap 11.72B
EPS -5.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Alnylam Announces FDA Acceptance Of New Drug Application (NDA) And Priority Review Status For Patisiran, An Investigational RNAi Therapeutic For The Treatment Of Hereditary ATTR (hATTR) Amyloidosis

Alnylam Announces FDA Acceptance Of New Drug Application (NDA) And Priority Review Status For Patisiran, An Investigational RNAi Therapeutic For The Treatment Of Hereditary ATTR (hATTR) Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.

Alnylam To Webcast Conference Call Discussing Fourth Quarter And Full Year 2017 Financial Results

Alnylam To Webcast Conference Call Discussing Fourth Quarter And Full Year 2017 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2017 on Thursday, February...

Alnylam Announces EMA Acceptance Of Marketing Authorisation Application (MAA) For Patisiran For The Treatment Of Hereditary ATTR (hATTR) Amyloidosis

Alnylam Announces EMA Acceptance Of Marketing Authorisation Application (MAA) For Patisiran For The Treatment Of Hereditary ATTR (hATTR) Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) and initiated its...

Alnylam Announces 2018 Corporate Goals

Alnylam Announces 2018 Corporate Goals

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced its corporate goals for 2018.

Alnylam And Sanofi Enter Into Strategic Restructuring Of RNAi Therapeutics Rare Disease Alliance

Alnylam And Sanofi Enter Into Strategic Restructuring Of RNAi Therapeutics Rare Disease Alliance

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Sanofi announced today a strategic restructuring of their RNAi therapeutics alliance to streamline and optimize development...

Alnylam Expands Alnylam Act™ Program To Include No-Charge Third-Party Genetic Testing And Counseling For People At Risk For Acute Hepatic Porphyrias

Alnylam Expands Alnylam Act™ Program To Include No-Charge Third-Party Genetic Testing And Counseling For People At Risk For Acute Hepatic Porphyrias

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it has expanded the Alnylam Act™ program to include no-charge, third-party genetic testing and counseling for...

Alnylam To Webcast Presentation At 36th Annual J.P. Morgan Healthcare Conference

Alnylam To Webcast Presentation At 36th Annual J.P. Morgan Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that management will present a company overview at the 36 th Annual J.

Alnylam To Webcast Presentation At Goldman Sachs Healthcare CEOs Unscripted Conference

Alnylam To Webcast Presentation At Goldman Sachs Healthcare CEOs Unscripted Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that management will present a company overview at the Goldman Sachs Healthcare CEOs Unscripted Conference on Thursday,...

Alnylam And Sanofi Submit Marketing Authorisation Application (MAA) To The European Medicines Agency (EMA) For Patisiran For The Treatment Of Hereditary ATTR (hATTR) Amyloidosis

Alnylam And Sanofi Submit Marketing Authorisation Application (MAA) To The European Medicines Agency (EMA) For Patisiran For The Treatment Of Hereditary ATTR (hATTR) Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today the submission of a Marketing Authorisation...

FDA Lifts Clinical Hold On Fitusiran

FDA Lifts Clinical Hold On Fitusiran

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that the U.

Alnylam Completes Submission Of New Drug Application To U.S. Food And Drug Administration (FDA) For Patisiran For The Treatment Of Hereditary ATTR (hATTR) Amyloidosis

Alnylam Completes Submission Of New Drug Application To U.S. Food And Drug Administration (FDA) For Patisiran For The Treatment Of Hereditary ATTR (hATTR) Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the completion of the rolling submission of a New Drug Application (NDA) to the U.

Alnylam Announces Expansion Of U.S. Orphan Drug Designation For Patisiran To Treatment Of Transthyretin-Mediated Amyloidosis

Alnylam Announces Expansion Of U.S. Orphan Drug Designation For Patisiran To Treatment Of Transthyretin-Mediated Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today the U.

Alnylam To Webcast Presentation At BMO Capital Markets Prescriptions For Success Healthcare Conference

Alnylam To Webcast Presentation At BMO Capital Markets Prescriptions For Success Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that management will present a company overview at the BMO Capital Markets 2017 Prescriptions for Success Healthcare...

U.S. Food And Drug Administration (FDA) Grants Alnylam Breakthrough Therapy Designation (BTD) For Patisiran For The Treatment Of Hereditary ATTR (hATTR) Amyloidosis With Polyneuropathy

U.S. Food And Drug Administration (FDA) Grants Alnylam Breakthrough Therapy Designation (BTD) For Patisiran For The Treatment Of Hereditary ATTR (hATTR) Amyloidosis With Polyneuropathy

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the U.

Alnylam Pharmaceuticals Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

Alnylam Pharmaceuticals Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the closing of its previously announced underwritten registered public offering of 6,440,000 shares of its common stock,...

Alnylam Initiates Rolling Submission Of New Drug Application (NDA) To U.S. Food And Drug Administration (FDA) For Patisiran For The Treatment Of Hereditary ATTR (hATTR) Amyloidosis

Alnylam Initiates Rolling Submission Of New Drug Application (NDA) To U.S. Food And Drug Administration (FDA) For Patisiran For The Treatment Of Hereditary ATTR (hATTR) Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the company has initiated submission of a rolling New Drug Application (NDA) to the U.

Alnylam Pharmaceuticals Prices Public Offering Of Common Stock

Alnylam Pharmaceuticals Prices Public Offering Of Common Stock

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the pricing of an underwritten registered public offering of 5,600,000 shares of its common stock at a public offering...

European Medicines Agency (EMA) Grants Alnylam Accelerated Assessment Of Patisiran For Patients With Hereditary ATTR (hATTR) Amyloidosis

European Medicines Agency (EMA) Grants Alnylam Accelerated Assessment Of Patisiran For Patients With Hereditary ATTR (hATTR) Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted an...

Alnylam Pharmaceuticals Announces Proposed Public Offering Of $675,000,000 Of Common Stock

Alnylam Pharmaceuticals Announces Proposed Public Offering Of $675,000,000 Of Common Stock

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced the commencement of an underwritten public offering of shares of its common stock to raise aggregate proceeds of...

Alnylam Announces Successful Outcome Following FDA Type A Meeting To Discuss Fitusiran Program In Hemophilia

Alnylam Announces Successful Outcome Following FDA Type A Meeting To Discuss Fitusiran Program In Hemophilia

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today a successful Type A meeting with the U.

Alnylam Pharmaceuticals Reports Third Quarter 2017 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals Reports Third Quarter 2017 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter 2017, and highlighted recent progress in advancing its...

Alnylam Initiates ENVISION Phase 3 Clinical Study With Givosiran, An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyrias (AHPs)

Alnylam Initiates ENVISION Phase 3 Clinical Study With Givosiran, An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyrias (AHPs)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the initiation of the ENVISION Phase 3 clinical study with givosiran, a subcutaneously administered, investigational...

The Medicines Company And Alnylam Pharmaceuticals Announce Initiation Of Phase III Clinical Trials Of Inclisiran

The Medicines Company And Alnylam Pharmaceuticals Announce Initiation Of Phase III Clinical Trials Of Inclisiran

The Medicines Company (NASDAQ: MDCO) and Alnylam Pharmaceuticals, Inc.

Alnylam Reports Positive Preliminary Results From Ongoing Phase 1/2 Study Of Lumasiran (ALN-GO1) In Patients With Primary Hyperoxaluria Type 1 (PH1)

Alnylam Reports Positive Preliminary Results From Ongoing Phase 1/2 Study Of Lumasiran (ALN-GO1) In Patients With Primary Hyperoxaluria Type 1 (PH1)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive preliminary data from its ongoing Phase 1/2 study with lumasiran (formerly known as ALN-GO1), an...

Notable Thursday Option Activity: ALNY, NTLA, IMMR

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Alnylam Pharmaceuticals Inc , where a total volume of 8,996 contracts has been traded thus far today, a contract volume which is representative of approximately 899,600 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 93.8% of ALNY's average daily trading volume over the past month, of 959,440 shares.

Alnylam And Sanofi Present Positive Complete Results From APOLLO Phase 3 Study Of Investigational Patisiran In Hereditary ATTR (hATTR) Amyloidosis Patients With Polyneuropathy

Alnylam And Sanofi Present Positive Complete Results From APOLLO Phase 3 Study Of Investigational Patisiran In Hereditary ATTR (hATTR) Amyloidosis Patients With Polyneuropathy

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today positive complete results from the APOLLO...

Alnylam To Webcast Presentations At Upcoming November Investor Conferences

Alnylam To Webcast Presentations At Upcoming November Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: 26 th Annual Credit...

Alnylam To Webcast Conference Call Discussing Third Quarter 2017 Financial Results

Alnylam To Webcast Conference Call Discussing Third Quarter 2017 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2017 on Tuesday, November 7, 2017,...

TheStreet Quant Rating: D (Sell)